Table 1.
Patient # | Age | Subtype | Grade | LN MTS | Organ MTS | SUVmax | T/B ratio | Visible |
---|---|---|---|---|---|---|---|---|
1 | 61 | NST | G2 | − | − | 3.2 | 2.9 | + |
2 | 58 | NST | G3 | + | + | 4.3 | 3.9 | + |
3 | 49 | ILC | G3 | + | − | 1.7 | 1.0 | − |
4 | 51 | NST | G2 | + | + | 2.0 | 2.0 | + |
5 | 53 | NST | G2 | − | − | 2.9 | 2.6 | + |
6 | 56 | NST | G2 | − | − | 1.9 | 1.6 | − |
7 | 38 | NST | G2 | + | − | 2.8 | 2.3 | + |
8 | 69 | NST | G2 | + | − | 3.2 | 3.6 | + |
9 | 50 | NST | G2 | − | − | 4.5 | 3.5 | + |
10 | 47 | ILC | G2 | − | + | 1.8 | 1.0 | − |
11 | 40 | NST | G2 | − | − | 1.8 | 1.0 | − |
12 | 67 | NST | G2 | − | − | 2.9 | 1.6 | + |
13 | 48 | NST | G3 | − | − | 5.7 | 3.8 | + |
In 9 of 13 patients, the primary tumor was visually detectable (last row)
NST invasive carcinoma of no special type, ILC invasive lobular carcinoma